Mater-Director-of-Infectious-Diseases-Dr-Paul-Griffin

Prof Paul Griffin

Infectious Diseases Physician and Clinical Microbiologist; Director of Infectious Diseases, Mater Hospital; Lecturer, University of Queensland
An Infectious Diseases Physician and Clinical Microbiologist, Prof Paul Griffin was appointed as the Director of Infectious Diseases at Mater Health Services in 2013, and most recently, to his conjoint role as Head of the Mater Clinical Unit for the University of Queensland School of Medicine. Prof Griffin is an accomplished clinical trial investigator, having fulfilled the role of Principal Investigator in over 150 clinical trials, particularly in Infectious Diseases including 8 COVID-19 vaccines. Despite an already demanding role at the Mater, Prof Griffin continues as a member of the AMA Queensland Council 2023-2024, and as board member and scientific advisory board member of the Immunisation Coalition, with active interest in vaccine education and advocacy, becoming a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

More from this expert

Podcasts iconPodcasts

COVID is still very much around, and older people are still most at risk of significant morbidity. We discuss management strategies, both in the community and in facilities, that can be beneficial in mitigating this risk.

Videos iconVideos

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

Podcasts iconPodcasts

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

Videos iconVideos

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).

Podcasts iconPodcasts

A high index of suspicion based on vaccination status, travel and exposure history will help raise a red flag- GPs are once again at the forefront of identifying, treating and ensuring that we commence the appropriate public health interventions.

Ba2, Deltacron, Omicron and other variants- the winter booster - for which patients? An update on the other vaccines and the COVID antivirals.

Podcasts iconPodcasts

This mosquito-transmitted disease has already killed a handful of people, and is likely to become more common- an effective vaccine will soon be made widely available to those at risk.

Podcasts iconPodcasts

New advice on when to vaccinate after COVID infection

Podcasts iconPodcasts

A high index of suspicion based on vaccination status, travel and exposure history will help raise a red flag- GPs are once again at the forefront of identifying, treating and ensuring that we commence the appropriate public health interventions.

Podcasts iconPodcasts

Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed

Podcasts iconPodcasts

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).

Videos iconVideos

The new COVID wave comprising of BQ1, XBB and other variants, and what our frontline response should look like, whether a fifth booster is worth having, children's vaccination developments and an update on the antivirals

Podcasts iconPodcasts

In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access (8 mins).

Videos iconVideos

Basic statistics, epidemiology, and important events, and new variants and subvariants

Podcasts iconPodcasts

COVID is still very much around, and older people are still most at risk of significant morbidity. We discuss management strategies, both in the community and in facilities, that can be beneficial in mitigating this risk.

Podcasts iconPodcasts